DOCPHARMA
ActiveFrom the official registers: KBO 31 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
DOCPHARMA has been active since 1999 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €36.6m and a net result of €581,444. Equity remains stable across the filed financial years (±1.4% per year). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Official details
KBO- Status
- Active since 05-03-1999 Normal situation
- Legal form
- Private limited company
- Registered office
- Terhulpsesteenweg 6, 1560 Hoeilaart
- Activity
- “Alle industriële,commerciële verrichtingen met betrekking tot de chemische,farmaceutische,dieetvoeding- en cosmeticaproducten;” (deed in Dutch)From the articles, 7 activitiesNo NACE code in the KBO yet
- Establishment unit
- 2.103.154.988 1560 Hoeilaart, since 23-11-1999
- Financial year end
- 31 December
- Peppol
- Reachable since 20-11-2020
Who decides
Board
- Tomasz BuczekDirector · since 25-06-2025
- ArunNarayanDirector · since 26-11-2025
Shareholders
- Viatris GX100%annual accounts 2025
- Viatris Inc.consolidatesannual accounts 2020
- Holdings
- Shares in 1 company AKTUAPHARMA
How it is doing
- Bankruptcy probabilitywithin 12 months
- 0.3%
Annual accounts 2025
- Profit
- €581,444
- ▼ 51.8%
- Equity
- €36.6m
- ▲ 1.6%
- Total assets
- €48.2m
- ▲ 2.2%
2025 accounts 24 days early
Filed on 07-07-2026at the National Bank
Why 88raises riskLiquidity: current ratio 3522.44No main activity registeredlowers riskSize: total assets €48.2mFounded in 1999Show the evidence
Checked score
Score 2025
88
/ 100
Excellent
Probability in this band: under 0.55%
Financially better than 69% of its sector peers (no NACE code, large)
Financial strength · tick = 2024
Strong
Solvency
100=
equity 75.8% of total assets
Liquidity
100=
short-term debt 0.0%
Profitability
41-3
return on assets 1.2%
Bankruptcy probability, 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.3%
12-2024: 0.3%● unchanged vs 11-2024
01-2025: 0.3%● unchanged vs 12-2024
02-2025: 0.3%● unchanged vs 01-2025
03-2025: 0.3%● unchanged vs 02-2025
04-2025: 0.3%● unchanged vs 03-2025
05-2025: 0.3%● unchanged vs 04-2025
06-2025: 0.3%● unchanged vs 05-2025
07-2025: 0.4%▲ +0.1 percentage points vs 06-2025highest value
08-2025: 0.3%▼ -0.1 percentage points vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.3%● unchanged vs 11-2025
01-2026: 0.3%● unchanged vs 12-2025
02-2026: 0.3%● unchanged vs 01-2026
03-2026: 0.3%● unchanged vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.3%● unchanged vs 05-2026
07-2026: 0.3%● unchanged vs 06-2026
08-2026: 0.3%● unchanged vs 07-2026lowest value
09-2026: 0.3%● unchanged vs 08-2026lowest value
10-2026: 0.3%● unchanged vs 09-2026lowest value
Credit of up to €3,200,000 on 30-day terms is acceptable
short-term debt: 0% of total assets, and 24.2% of the assets are financed with debt and provisions.
How it is calculated
The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, large): better than 67% on solvency, 98% on liquidity, 60% on profitability and 52% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises riskneutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 days early
2024
34 days early
2023
34 days early
2022
20 days early
2021
24 days early
2020
18 days early
2019
22 days early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 7 accounts on average 25 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 7 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials · financial year 2025, full format
Latest annual accounts filed
Annual accounts 2025
- Financial year ended
- 31-12-2025
- Filed on
- 07-07-2026
- Format
- full format
- Reference
- 2026-00280438
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€581,444▼ 51.8%
2024 · €1.2m
Working capital
€48.2m▲ 2.2%
2024 · €47.2m
Trend over the years
2021 to 2025, 5 financial years 2018 to 2025, 8 financial years
The operating result stays negative: a loss of €476,575 in 2025 against €469,053 in 2024; the loss grows and 2025 has the lowest result in the available series.
What the company sold each financial year and what was left of it. A loss stands below the zero line.
Operating result-€0.5m
2025
Net result€0.6m
2025
What the company owns (total assets), how much of it is its own (equity) and how much it owes.
Total assets€48.2m
2025
Equity€36.6m
2025
Debt€0.01m
2025
Short-term assets minus short-term debts. Above zero the company can pay its bills in the short term.
Working capital€48.2m
2025
Use the arrow keys on the chart for the figures per year.
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result-€0.5m--€0.5m▼ 0.7%-€0.4m▲ 8.9%-€0.5m▼ 12.5%-€0.4m▲ 8.5%-€0.5m▼ 7.2%-€0.5m▼ 1.0%-€0.5m▼ 1.6%
Net result-€0.5m--€0.5m▼ 0.8%-€0.4m▲ 10.1%-€0.5m▼ 12.7%€1.2m€0.8m▼ 36.2%€1.2m▲ 53.0%€0.6m▼ 51.8%
Equity€34.1m-€33.6m▼ 1.4%€33.2m▼ 1.2%€32.7m▼ 1.4%€34.0m▲ 3.8%€34.8m▲ 2.3%€36.0m▲ 3.5%€36.6m▲ 1.6%
Total assets€47.8m-€47.8m=€47.8m▲ 0.1%€47.8m=€44.3m▼ 7.4%€45.5m▲ 2.8%€47.2m▲ 3.6%€48.2m▲ 2.2%
Debt€0.01m-€0.01m▲ 3.1%€0.002m▼ 82.7%€0.02m▲ 559%€0.01m▼ 5.7%€0.03m▲ 91.5%€0.01m▼ 55.0%€0.01m▲ 9.8%
Working capital€47.8m-€47.8m=€47.8m▲ 0.1%€47.8m=€44.3m▼ 7.4%€45.5m▲ 2.8%€47.2m▲ 3.6%€48.2m▲ 2.2%
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Equity and liabilities €48.2m
Equity
€36.6m ▲ 1.6%
Provisions
€11.6m ▲ 4.0%
Debt
€13,685 ▲ 9.8%
Debt's share of the balance-sheet total stays at 0.0%.
Key figures and ratios
Debt to equity
0.00▲
2024 · 0.00
ROE
1.6%▼
2024 · 3.4%
ROA
1.2%▼
2024 · 2.6%
Debt ≤ 1 year
€13,685▲
2024 · €12,465
A ratio outside any meaningful range has been withheld (balance sheet total €48.2m, equity €36.6m).
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 513 companies that looked in July 2024 the way this one looks now, 0.8% went bankrupt within 24 months and 96.1% are still going.
- Large
- 20 years or older
- solvency 30% or more
- a profit under 5% of the balance sheet
0.8%
went bankrupt
3.1%
stopped otherwise
96.1%
still going
For this company itself Checked computes a bankruptcy probability of 0.3% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,445 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 513 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Operating income70/76A | - | - | - | - | €0.04m | €0.004m | - | - | - |
| Other operating income74 | - | - | - | - | €0.04m | €0.004m | - | - | - |
| Operating charges60/66A | - | - | - | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | ▲ 1.6% |
| Services and other goods61 | - | - | - | €0.02m | €0.02m | €0.02m | €0.02m | €0.02m | ▲ 54.1% |
| Remuneration, social security and pensions62 | - | - | - | - | - | €142 | - | - | - |
| Provisions for liabilities and charges: additions (uses and reversals)635/8 | - | - | - | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | ▼ 0.3% |
| Operating profit (loss)9901 | -€0.5m | -€0.5m | -€0.4m | -€0.5m | -€0.4m | -€0.5m | -€0.5m | -€0.5m | ▼ 1.6% |
| Financial income75/76B | - | - | - | - | €1.7m | €1.3m | €1.7m | €1.1m | ▼ 37.6% |
| Recurring financial income75 | €0.009m | €0.009m | €0.009m | €0.009m | €0.009m | €1.3m | €1.7m | €1.1m | ▼ 37.6% |
| Income from current assets751 | - | - | - | €0.009m | €0.009m | €1.3m | €1.7m | €1.1m | ▼ 37.6% |
| Other financial income752/9 | - | - | - | - | - | €0 | €0 | €0 | - |
| Non-recurring financial income76B | - | - | - | - | €1.7m | - | - | - | - |
| Financial charges65/66B | - | - | - | €0.001m | €0.001m | €0.002m | €0.002m | €0.001m | ▼ 59.4% |
| Recurring financial charges65 | €0.007m | €0.007m | €0.001m | €0.001m | €0.001m | €0.002m | €0.002m | €0.001m | ▼ 59.4% |
| Other financial charges652/9 | - | - | - | €0.001m | €0.001m | €0.002m | €0.002m | €0.001m | ▼ 59.4% |
| Profit (loss) for the period before taxes9903 | -€0.5m | -€0.5m | -€0.4m | -€0.5m | €1.2m | €0.8m | €1.2m | €0.6m | ▼ 52.6% |
| Income taxes67/77 | -€16 | - | - | - | - | €0.01m | €0.02m | - | - |
| Taxes670/3 | - | - | - | - | - | €0.01m | €0.02m | - | - |
| Profit (loss) for the period9904 | -€0.5m | -€0.5m | -€0.4m | -€0.5m | €1.2m | €0.8m | €1.2m | €0.6m | ▼ 51.8% |
| Profit (loss) for the period to be appropriated9905 | -€0.5m | -€0.5m | -€0.4m | -€0.5m | €1.2m | €0.8m | €1.2m | €0.6m | ▼ 51.8% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €47.8m | €47.8m | €47.8m | €47.8m | €44.3m | €45.5m | €47.2m | €48.2m | ▲ 2.2% |
| Formation expenses20 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Fixed assets21/28 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Tangible fixed assets22/27 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Furniture and vehicles24 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Financial fixed assets28 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Affiliated companies280/1 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Participating interests280 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Current assets29/58 | €47.8m | €47.8m | €47.8m | €47.8m | €44.3m | €45.5m | €47.2m | €48.2m | ▲ 2.2% |
| Amounts receivable within one year40/41 | €47.8m | €47.7m | €47.8m | €47.8m | €44.2m | €45.5m | €47.2m | €48.2m | ▲ 2.2% |
| Other amounts receivable41 | - | - | - | €47.8m | €44.2m | €45.5m | €47.2m | €48.2m | ▲ 2.2% |
| Cash at bank and in hand54/58 | €0.03m | €0.05m | €0.05m | €0.05m | €0.05m | €0 | - | - | - |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €47.8m | €47.8m | €47.8m | €47.8m | €44.3m | €45.5m | €47.2m | €48.2m | ▲ 2.2% |
| Equity10/15 | €34.1m | €33.6m | €33.2m | €32.7m | €34.0m | €34.8m | €36.0m | €36.6m | ▲ 1.6% |
| Contributions10/11 | €57.6m | €57.6m | - | €83.3m | €83.3m | €83.3m | €83.3m | €83.3m | = |
| Profit (loss) carried forward14 | -€49.2m | -€49.7m | -€50.1m | -€50.6m | -€49.3m | -€48.5m | -€47.3m | -€46.7m | ▲ 1.2% |
| Provisions and deferred taxes16 | €13.7m | €14.2m | €14.6m | €15.1m | €10.3m | €10.7m | €11.2m | €11.6m | ▲ 4.0% |
| Provisions for liabilities and charges160/5 | - | - | - | €15.1m | €10.3m | €10.7m | €11.2m | €11.6m | ▲ 4.0% |
| Other liabilities and charges164/5 | - | - | - | €15.1m | €10.3m | €10.7m | €11.2m | €11.6m | ▲ 4.0% |
| Amounts payable17/49 | €0.01m | €0.01m | €0.002m | €0.02m | €0.01m | €0.03m | €0.01m | €0.01m | ▲ 9.8% |
| Amounts payable within one year42/48 | €0.01m | €0.01m | €0.002m | €0.02m | €0.01m | €0.03m | €0.01m | €0.01m | ▲ 9.8% |
| Trade debts44 | €0.01m | €0.01m | - | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | ▲ 9.8% |
| Suppliers440/4 | - | - | - | €0.01m | €0.01m | €0.01m | €0.01m | €0.01m | ▲ 9.8% |
| Taxes, remuneration and social security45 | - | - | - | €0.002m | €0.002m | €0.02m | - | - | - |
| Taxes450/3 | - | - | - | €0.002m | €0.002m | €0.02m | - | - | - |
| Other amounts payable47/48 | - | - | - | - | €0 | €0 | €0 | €0 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€0.5m | -€0.5m | -€0.4m | -€0.5m | €1.2m | €0.8m | €1.2m | €0.6m | ▼ 51.8% |
| Operating cash flow (approximation) | -€0.5m | -€0.5m | -€0.4m | -€0.5m | €1.2m | €0.8m | €1.2m | €0.6m | ▼ 51.8% |
| Investment in fixed assets (approximation) | - | - | - | - | - | €0 | €0 | €0 | - |
| Change in cash | - | €0.02m | -€0.001m | -€0.001m | -€0.001m | -€0.05m | - | - | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Latest 10 of 31 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 07-07-2026 | 2026-00280438 | NBB |
| 31-12-2024 | full format | 27-06-2025 | 2025-00233142 | |
| 31-12-2023 | full format | 27-06-2024 | 2024-00222387 | |
| 31-12-2022 | full format | 11-07-2023 | 2023-00241426 | |
| 31-12-2021 | full format | 07-07-2022 | 2022-20197506 | |
| 31-12-2020 | full format | 13-07-2021 | 2021-36600229 | |
| 31-12-2019 | full format | 09-07-2020 | 2020-28000426 | |
| 31-12-2018 | full format | 09-07-2019 | 2019-31700312 | |
| 31-12-2017 | full format | 04-07-2018 | 2018-30600118 | |
| 31-12-2016 | full format | 13-09-2017 | 2017-61100555 |
Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.
Directors
Directors
2 directors, no change since 2025
Statutory auditor 1
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
Current
Statutory auditor · appointed in the act of 10-08-2009 · permanent representative: Tom Renders
Mandate history
33 people, 3 in office
- Board
- Day-to-day management
- Statutory auditor
- Other function
- began earlier
- end not dated
| Name | Functions and periods |
|---|---|
| Tomasz Buczek |
|
| ArunNarayan |
|
| Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises |
|
| MatthewSalzmann |
|
| Vincent Verschraegen |
|
| Matthew Salzmann |
|
| Luis Birbuet |
|
| José Cotarelo |
|
| Anthonius van 't Hullenaar |
|
| Maximilian von Wülfing |
|
| Jens Neuschaefer |
|
| Yves Brigode |
|
| Khadija Badli |
|
| Gary Sphar |
|
| Mylan BVBA |
|
| Pascale Engelen |
|
| Barret Didier Henri |
|
| Heather Bresch |
|
| Bouldoires Vincent |
|
| Malik Rajiv |
|
| Seshan Srinivasan |
|
| Nimmagadda Prasad |
|
| Bouldoires Vincent Pierre |
|
| Bresch Heather Mangrin |
|
| Edward Borkowski |
|
| Robert Coury |
|
| C Ramakrishna |
|
| C.S Murali |
|
| Matrix Laboratories NV |
|
| Anthony Herbert Bloom |
|
| Van Rompay Management |
|
| Etienne Lenoir |
|
| Maarten Coolen |
|
How the board is organised
- Who signsWho may bind the company towards others, for example by signing a contract.
- Each director alone
- Board ruleHow the board is made up, meets and takes decisions.
- One provision in the deed
Articles of association, deed of 10-07-2025
Owners and capital
Owners
2 ownersChain of control
- Viatris Inc.US
- Viatris GX
- DOCPHARMA
Owners 2
-
100%
- Viatris Inc.USconsolidating parentconsolidates
Capital and shareholders
Capital over the years
- 25-01-2024 Converted to unavailable equity
- 25-01-2024 Converted to available equity
- 25-02-2010 Capital stated in the deed · €57,578,062.74 · 6,297,570 shares
Shares according to the articles of association
Capital, shares and profit
- Transfer restrictionWhether shareholders may sell their shares freely or need approval first.
- One provision in the deed
deed of 25-01-2024 (in Dutch)
Other provisionsRules from the articles on subjects other than the board, the shares, the purpose and the meetings.
Group and network
Holdings and subsidiaries
1 holdingHoldings 1
-
99.99%
Connections & network
2 current directorsThe board mandates are listed below; here you explore them as a network.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Board mandates elsewhere
2 board mandatesBoard mandates of this companythis company sits on their board2
1 location
1 location
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
07-07
financial year 2025 · full format
02-07
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Tom Renders3 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representative: Tom Renders3 facts ▸
- General meeting, 18-06-2026
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Tom Renders
2025
10-12
Gazette deed
Resignation: MatthewSalzmann (director)Appointment: ArunNarayan (director)4 facts ▸
Gazette deed
Resignation: MatthewSalzmann (director)
Appointment: ArunNarayan (director)4 facts ▸
- General meeting, 25-11-2025
- Director resignation, MatthewSalzmann (director)
- Other provision, “kwijtingontslagnemendebestuurder, beginlopendeboekjaartot2025-11-26” (deed in Dutch)
- Director appointment, ArunNarayan (director)
10-07
Gazette deed
Resignation: Vincent Verschraegen (director)Appointment: Tomasz Buczek (director)3 facts ▸
Gazette deed
Resignation: Vincent Verschraegen (director)
Appointment: Tomasz Buczek (director)3 facts ▸
- General meeting, 24-06-2025
- Director resignation, Vincent Verschraegen (director)
- Director appointment, Tomasz Buczek (director)
27-06
financial year 2024 · full format
2024
31-12
Financial
Liquidity more than doubledcurrent ratio 3784.05
Current ratio from 1643.12 to 3784.05; short-term debt falls from €27,707 to €12,465.
27-06
financial year 2023 · full format
21-03
Gazette deed
Resignation: Luis Birbuet (director)Appointment: Matthew Salzmann (director) · Director discharge4 facts ▸
Gazette deed
Resignation: Luis Birbuet (director)
Appointment: Matthew Salzmann (director) · Director discharge4 facts ▸
- General meeting, 28-02-2024
- Director resignation, Luis Birbuet (director)
- Director discharge, Luis Birbuet (2 times)
- Director appointment, Matthew Salzmann (director)
25-01
Gazette deed
Amendment of the articles · Legal-form change · Name · Resignations & appointmentsCapital conversion · Capital · Power of attorney7 facts ▸
Gazette deed
Amendment of the articles · Legal-form change · Name · Resignations & appointments
Capital conversion · Capital · Power of attorney7 facts ▸
- General meeting, 26-12-2023
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Capital conversion, “beschikbare eigen vermogensrekening” (deed in Dutch)
- Amendment of the articles
- Capital
- Power of attorney
- Power of attorney, Yorik DESMYTTERE
2023
11-07
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)2 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
2 facts ▸
- General meeting, 28-06-2023
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
11-07
financial year 2022 · full format
2022
31-12
Financial
Back to profitnet €1.2m
Net result €1.2m after 4 loss-making years.
Show earlier events
07-07
financial year 2021 · full format
2021
31-12
Financial
Weakest financial yearnet -€466,245
Net result drops to -€466,245, the lowest in the series; recovery starts the following year.
13-07
financial year 2020 · full format
14-04
Gazette deed
Resignation: José Cotarelo (director)Appointment: Luis Birbuet (director) · Mandate compensation6 facts ▸
Gazette deed
Resignation: José Cotarelo (director)
Appointment: Luis Birbuet (director) · Mandate compensation6 facts ▸
- General meeting, 30-03-2021
- Director resignation, José Cotarelo (director)
- Director appointment, Luis Birbuet (director)
- Mandate compensation, Luis Birbuet
- Board composition, Vincent Verschraegen (director)
- Board composition, Luis Birbuet (director)
2020
31-12
Financial
Liquidity more than 5 timescurrent ratio 20546.75
Current ratio from 3553.83 to 20546.75; short-term debt falls from €13,447 to €2,327.
14-07
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)Power of attorney3 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
Power of attorney3 facts ▸
- General meeting, 18-06-2020
- Auditor reappointment, Deloitte Bedrijfsrevisoren
- Power of attorney, Joanna Bochner
09-07
financial year 2019 · full format
2019
09-07
financial year 2018 · full format
08-02
Gazette deed
Resignations: Anthonius van 't Hullenaar (manager) and Maximilian von Wülfing (manager)Appointments: Vincent Verschraegen (manager) and Jose Cotarelo (manager) · Permanent representative: Vincent Verschraegen · Mandate compensation9 facts ▸
Gazette deed
Resignations: Anthonius van 't Hullenaar (manager) and Maximilian von Wülfing (manager)
Appointments: Vincent Verschraegen (manager) and Jose Cotarelo (manager) · Permanent representative: Vincent Verschraegen · Mandate compensation9 facts ▸
- General meeting, 20-12-2018
- Director resignation, Anthonius van 't Hullenaar (manager)
- Director resignation, Maximilian von Wülfing (manager)
- Director appointment, Vincent Verschraegen (manager)
- Director appointment, Jose Cotarelo (manager)
- Mandate compensation, Vincent Verschraegen
- Mandate compensation, Jose Cotarelo
- Board meeting, 20-12-2018
- Permanent representative, Vincent Verschraegen
2018
04-07
financial year 2017 · full format
2017
05-10
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)2 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
2 facts ▸
- General meeting, 30-08-2017
- Auditor reappointment, Deloitte Bedrijfsrevisoren
13-09
financial year 2016 · full format · 44 days late
05-05
Gazette deed
Resignation: Jens Neuschaefer (manager)Appointments: Anthonius van 't Hullenaar (manager) and Maximilian von Wülfing (manager) · Permanent representative: Anthonius van 't Hullenaar · Mandate compensation8 facts ▸
Gazette deed
Resignation: Jens Neuschaefer (manager)
Appointments: Anthonius van 't Hullenaar (manager) and Maximilian von Wülfing (manager) · Permanent representative: Anthonius van 't Hullenaar · Mandate compensation8 facts ▸
- General meeting, 15-03-2017
- Director resignation, Jens Neuschaefer (manager)
- Director appointment, Anthonius van 't Hullenaar (manager)
- Director appointment, Maximilian von Wülfing (manager)
- Mandate compensation, Anthonius van 't Hullenaar
- Mandate compensation, Maximilian von Wülfing
- Board meeting, 15-03-2017
- Permanent representative, Anthonius van 't Hullenaar
24-01
Gazette deed
Resignation: Yves Brigode (manager)3 facts ▸
Gazette deed
Resignation: Yves Brigode (manager)
3 facts ▸
- General meeting, 05-01-2017
- Director resignation, Yves Brigode (manager)
- Board composition, Jens Neuschaefer (manager)
2016
15-09
Gazette deed
Appointment: Jens Neuschaefer (manager)Mandate compensation3 facts ▸
Gazette deed
Appointment: Jens Neuschaefer (manager)
Mandate compensation3 facts ▸
- General meeting, 08-08-2016
- Director appointment, Jens Neuschaefer (manager)
- Mandate compensation, Jens Neuschaefer
2015
09-09
Gazette deed
Resignation: Khadija Badli (manager)Appointment: Yves Brigode (manager) · Mandate compensation · Power of attorney6 facts ▸
Gazette deed
Resignation: Khadija Badli (manager)
Appointment: Yves Brigode (manager) · Mandate compensation · Power of attorney6 facts ▸
- General meeting, 20-08-2015
- Director resignation, Khadija Badli (manager)
- Director appointment, Yves Brigode (manager)
- Mandate compensation, Yves Brigode
- Power of attorney, Yves Brigode
- Power of attorney, Karen Laevaert
28-01
Gazette deed
Resignation: Gary Sphar (manager)Power of attorney3 facts ▸
Gazette deed
Resignation: Gary Sphar (manager)
Power of attorney3 facts ▸
- General meeting, 30-12-2014
- Director resignation, Gary Sphar (manager)
- Power of attorney, Karen Laevaert
2014
23-07
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)Power of attorney3 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
Power of attorney3 facts ▸
- General meeting, 19-06-2014
- Auditor reappointment, Deloitte Bedrijfsrevisoren
- Power of attorney, Karen Laevaert
2013
30-12
Gazette deed
Resignation: Mylan BVBA (manager)Appointment: Khadija Badli (manager) · Mandate compensation4 facts ▸
Gazette deed
Resignation: Mylan BVBA (manager)
Appointment: Khadija Badli (manager) · Mandate compensation4 facts ▸
- General meeting, 11-12-2013
- Director resignation, Mylan BVBA (manager)
- Director appointment, Khadija Badli (manager)
- Mandate compensation, Khadija Badli
02-10
Gazette deed
Resignation: Pascale Engelen (manager)Appointment: Mylan BVBA (manager) · Mandate compensation4 facts ▸
Gazette deed
Resignation: Pascale Engelen (manager)
Appointment: Mylan BVBA (manager) · Mandate compensation4 facts ▸
- General meeting, 28-08-2013
- Director resignation, Pascale Engelen (manager)
- Director appointment, Mylan BVBA (manager)
- Mandate compensation, Mylan BVBA
10-01
Gazette deed
Resignation: Didier Barret (manager)Appointment: Gary Sphar (manager) · Mandate compensation4 facts ▸
Gazette deed
Resignation: Didier Barret (manager)
Appointment: Gary Sphar (manager) · Mandate compensation4 facts ▸
- General meeting, 20-12-2012
- Director resignation, Didier Barret (manager)
- Director appointment, Gary Sphar (manager)
- Mandate compensation, Gary Sphar
2012
01-02
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)3 facts ▸
Gazette deed
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
3 facts ▸
- Board meeting, 09-01-2012
- General meeting, 11-01-2012
- Auditor reappointment, Deloitte Bedrijfsrevisoren
2011
07-04
Gazette deed
Resignation: Heather Bresch (manager)2 facts ▸
Gazette deed
Resignation: Heather Bresch (manager)
2 facts ▸
- General meeting, 17-03-2011
- Director resignation, Heather Bresch (manager)
16-03
Gazette deed
Resignations: Seshan Srinivasan, Malik Rajiv and Bouldoires VincentAppointment: Pascale Engelen (manager) · Mandate compensation6 facts ▸
Gazette deed
Resignations: Seshan Srinivasan, Malik Rajiv and Bouldoires Vincent
Appointment: Pascale Engelen (manager) · Mandate compensation6 facts ▸
- General meeting, 21-02-2011
- Director resignation, Seshan Srinivasan (manager)
- Director resignation, Malik Rajiv (manager)
- Director resignation, Bouldoires Vincent (manager)
- Director appointment, Pascale Engelen (manager)
- Mandate compensation, Pascale Engelen
2010
20-10
Gazette deed
Permanent representative: V. BouldoiresResignation: Prasad Nimmagadda (director) · Power of attorney6 facts ▸
Gazette deed
Permanent representative: V. Bouldoires
Resignation: Prasad Nimmagadda (director) · Power of attorney6 facts ▸
- Board meeting, 20-05-2010
- Permanent representative, V. Bouldoires
- Director resignation, Prasad Nimmagadda (director)
- General meeting, 17-06-2010
- Director resignation, Prasad Nimmagadda (manager)
- Power of attorney, Karen Laevaert
25-02
Gazette deed
Appointments: Bouldoires Vincent Pierre, Bresch Heather Mangrin and 4 othersResignation: Docpharma (director) · Legal-form conversion · Capital11 facts ▸
Gazette deed
Appointments: Bouldoires Vincent Pierre, Bresch Heather Mangrin and 4 others
Resignation: Docpharma (director) · Legal-form conversion · Capital11 facts ▸
- General meeting, 27-01-2010
- Legal-form conversion, “naamloze vennootschap -> besloten vennootschap met beperkte aansprakelijkheid” (deed in Dutch)
- Capital, €57,578,062.74
- Director appointment, Bouldoires Vincent Pierre (manager)
- Director appointment, Bresch Heather Mangrin (manager)
- Director appointment, Barret Didier Henri (manager)
- Director appointment, Seshan Srinivasan (manager)
- Director appointment, Nimmagadda Prasad (manager)
- Director appointment, Malik Rajiv (manager)
- Mandate compensation, Bouldoires Vincent Pierre
- Director resignation, Docpharma
20-01
Gazette deed
Amendment of the articlesAccounting effect3 facts ▸
Gazette deed
Amendment of the articles
Accounting effect3 facts ▸
- General meeting, 28-12-2009
- Amendment of the articles (2 times)
- Accounting effect, 01-04-2009
08-01
Gazette deed
Registered officeRegistered-office move2 facts ▸
Gazette deed
Registered office
Registered-office move2 facts ▸
- Board meeting, 11-12-2009
- Registered-office move, Terhulpsesteenweg 6A, 1560 Hoeilaart
2009
10-08
Gazette deed
Appointment: Vincent Bouldoires (general manager)Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)4 facts ▸
Gazette deed
Appointment: Vincent Bouldoires (general manager)
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)4 facts ▸
- Board meeting, 06-07-2009
- Director appointment, Vincent Bouldoires (general manager)
- General meeting, 20-07-2009
- Auditor reappointment, Deloitte Bedrijfsrevisoren
2007
26-02
Gazette deed
Resignations: C.S Murali, C Ramakrishna and Matrix Laboratories NVAppointments: Robert Coury, Edward Borkowski and Heather Bresch · Director discharge10 facts ▸
Gazette deed
Resignations: C.S Murali, C Ramakrishna and Matrix Laboratories NV
Appointments: Robert Coury, Edward Borkowski and Heather Bresch · Director discharge10 facts ▸
- General meeting, 08-02-2007
- Director resignation, C.S Murali (director)
- Director resignation, C Ramakrishna (director)
- Director resignation, Matrix Laboratories NV (director)
- Director discharge, C.S Murali
- Director discharge, C Ramakrishna
- Director discharge, Matrix Laboratories NV
- Director appointment, Robert Coury (director)
- Director appointment, Edward Borkowski (director)
- Director appointment, Heather Bresch (director)
2005
14-03
Gazette deed
Resignations: Etienne Lenoir (director) and Maarten Coolen (director)Appointment: Anthony Herbert Bloom (director) · Director discharge6 facts ▸
Gazette deed
Resignations: Etienne Lenoir (director) and Maarten Coolen (director)
Appointment: Anthony Herbert Bloom (director) · Director discharge6 facts ▸
- General meeting, 29-10-2004
- Director resignation, Etienne Lenoir (director)
- Director resignation, Maarten Coolen (director)
- Director discharge, Etienne Lenoir
- Director discharge, Maarten Coolen
- Director appointment, Anthony Herbert Bloom (director)
17-01
Gazette deed
Appointment: Van Rompay Management (afgevaardigd bestuurder)Permanent representative: Leon Van Rompay · Ratification4 facts ▸
Gazette deed
Appointment: Van Rompay Management (afgevaardigd bestuurder)
Permanent representative: Leon Van Rompay · Ratification4 facts ▸
- Board meeting, 21-12-2004
- Director appointment, Van Rompay Management (afgevaardigd bestuurder)
- Permanent representative, Leon Van Rompay
- Ratification, “alle handelingen gesteld in de hoedanigheid van afgevaardigd bestuurder sinds 24-11-2003” (deed in Dutch)
2004
19-07
Gazette deed
Resignations & appointmentsAmendment of the articles · Power of attorney4 facts ▸
Gazette deed
Resignations & appointments
Amendment of the articles · Power of attorney4 facts ▸
- General meeting, 02-07-2004
- Amendment of the articles
- Power of attorney, Leon Van Rompay
- Power of attorney, Stijn Van Rompay
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
Register details
Who it is
KBO recordName
DOCPHARMA in Dutch
Enterprise number
0465.350.075
Legal form
Private limited company
Status
Active, normale toestand
Founded
05-03-1999
Type
Legal entity
Where it is based
Registered office
Terhulpsesteenweg 6, 1560 Hoeilaart, Belgium
Establishments
1 establishment unit since 1999
Invoicing and payment
VAT number
BE 0465.350.075
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Scores and ratios are computed by Checked and are not a credit decision.
Purpose, financial year and meetings according to the articles of association
What the company does
- PurposeThe activities the company may carry out under its articles.
- “Alle industriële,commerciële verrichtingen met betrekking tot de chemische,farmaceutische,dieetvoeding- en cosmeticaproducten; Alle…”
7 activities
- Alle industriële,commerciële verrichtingen met betrekking tot de chemische,farmaceutische,dieetvoeding- en cosmeticaproducten;
- Alle industriële,commerciële verrichtingen met betrekking tot producten die dienstig zijn in de medische sector;
- Vertegenwoordiging en verkoop voor derden van allerlei materialen,toestellen en diensten,vertegenwoordiging,aan- en verkoop,im- en export,verhuur en installatie van medische apparatuur,pacemakers,medische en paramedische materialen en alle randapparatuur en toebehoren daarmee gepaard gaande,alsmede het onderhoud ervan;
- Alle verrichtingen van commerciële,industriële,onroerende,roerende en financiële aard,die rechtstreeks met dit voorwerp verwant of verknocht zijn,of de verwezenlijking ervan kunnen bevorderen;
- De vestiging en de uitbating van brevetten,merken,licenties en octrooien met betrekking tot de hierboven vermelde producten;
- De uitbating,de concessie,aankoop,verkoop en verhuur van de lokalen of onroerende goederen waarin de bovenvermelde activiteiten kunnen worden gerealiseerd en alle toebehoren;
- Belangenbehartiging t.a.v. prijzen en terugbetalingen t.o.v. diverse administraties en belangengroeperingen in de farmaceutische sector;
- DurationHow long the company exists; usually unlimited, so until it is dissolved.
- Unlimited
- Name clauseThe name the company operates under according to its articles.
- Docpharma
- Registered office clauseThe region of the registered office; it decides among other things the language of official documents.
- “Vlaamse gewest, enkel besluit van het bestuursorgaan”
Meetings and financial year
- Annual meetingWhen the shareholders meet each year, among other things to approve the annual accounts.
- Third Thursday of June at 17:00
Articles of association, deed of 25-01-2024 (in Dutch)
Environmental permits: No permit applications found in Flanders.
Sites & property
Registered office and establishments
1 establishment unit
Terhulpsesteenweg 6A, 1560 Hoeilaart
since 1999unit no. 2.103.154.988
Buildings and parcels at the addresses
Ground area
5,791 m²
Building footprint
1,094 m²
Building volume
11,847 m³
2 parcels, Flanders · tallest building 15.2 m.
2 parcels
Flanders
2
(100%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 23033C0075/00L019 | Flanders | 3,821 m² | 1 · 921 m² | 14.7 m · 4 |
| 23033C0073/00E009 | Flanders | 1,970 m² | 1 · 173 m² | 15.2 m · 2 |